metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis Using large-scale epidemiological evidence to help evaluate biomarkers in cardio...
Información de la revista
Vol. 22. Núm. S2.
16.º Simposio Científico Alimentación, Lípidos y Aterosclerosis
Páginas 33-35 (diciembre 2010)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 22. Núm. S2.
16.º Simposio Científico Alimentación, Lípidos y Aterosclerosis
Páginas 33-35 (diciembre 2010)
Acceso a texto completo
Using large-scale epidemiological evidence to help evaluate biomarkers in cardiovascular disease
Visitas
716
Emanuele di Angelantonio
University Lecturer in Medical Screening, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
References
[1.]
J.P. Ioannidis.
Why most published research findings are false.
[2.]
A.M. Wood, I.R. White, S.G. Thompson, S. Lewington, J. Danesh, Fibrinogen Studies Collaboration.
Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies.
Int J Epidemiol, 35 (2006), pp. 1570-1578
[3.]
J. Danesh, S. Erqou, M. Walker, S.G. Thompson, The Emerging Risk Factors Collaboration.
Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.
Eur J Epidemiol, 22 (2007), pp. 839-869
[4.]
E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, A. Thompson, Emerging Risk Factors Collaboration, et al.
Major lipids, apolipoproteins, and risk of vascular disease.
JAMA, 302 (2009), pp. 1993-2000
[5.]
J. Danesh, S. Lewington, S.G. Thompson, G.D. Lowe, R. Collins, Fibrinogen Studies Collaboration.
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.
JAMA, 294 (2005), pp. 1799-1809
[6.]
S. Kaptoge, I.R. White, S.G. Thompson, A.M. Wood, S. Lewington, G.D. Lowe, Fibrinogen Studies Collaboration, et al.
Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration.
Am J Epidemiol, 166 (2007), pp. 867-879
[7.]
G. Davey Smith, S. Ebrahim.
‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?.
Int J Epidemiol, 32 (2003), pp. 1-22
[8.]
B. Keavney, J. Danesh, S. Parish, A. Palmer, S. Clark, L. Youngman, et al.
Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’.
Int J Epidemiol, 35 (2006), pp. 935-943
[9.]
J. Danesh, A. Hingorani, F. Wensley, J.P. Casas, L. Smeeth, CRP CHD Genetics Collaboration.
Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation.
Eur J Epidemiol, 23 (2008), pp. 531-540
Copyright © 2010. Sociedad Española de Arteriosclerosis y Elsevier España S.L.
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.arteri.2023.10.002
No mostrar más